Download MendeleyStructure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.
Clark, C.G., Rossi, K.A., Corte, J.R., Fang, T., Smallheer, J.M., De Lucca, I., Nirschl, D.S., Orwat, M.J., Pinto, D.J.P., Hu, Z., Wang, Y., Yang, W., Jeon, Y., Ewing, W.R., Myers Jr., J.E., Sheriff, S., Lou, Z., Bozarth, J.M., Wu, Y., Rendina, A., Harper, T., Zheng, J., Xin, B., Xiang, Q., Luettgen, J.M., Seiffert, D.A., Wexler, R.R., Lam, P.Y.S.(2019) Bioorg Med Chem Lett 29: 126604-126604
- PubMed: 31445854 Search on PubMed
- DOI: https://doi.org/10.1016/j.bmcl.2019.08.008
- Primary Citation Related Structures:
5QQO, 5QQP - PubMed Abstract:
This manuscript describes the discovery of a series of macrocyclic inhibitors of FXIa with oral bioavailability. Assisted by structure based drug design and ligand bound X-ray crystal structures, the group linking the P1 moiety to the macrocyclic core was modified with the goal of reducing H-bond donors to improve pharmacokinetic performance versus 9. This effort resulted in the discovery of several cyclic P1 linkers, exemplified by 10, that are constrained mimics of the bioactive conformation displayed by the acrylamide linker of 9. These cyclic P1 linkers demonstrated enhanced bioavailability and improved potency.
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States. Electronic address: charles.clark@bms.com.
Organizational Affiliation:
